OBJECTIVES: Reoperation for failing stentless aortic valve replacement is a technically demanding procedure that has traditionally been tackled in one of two ways: either root replacement or the more conservative option of implanting a stented valve within the valve. We sought to determine the relative operative risks, follow-up status and medium to long-term survival of these two methods.
INTRODUCTION

Stentless valves: pros and cons
Stentless aortic valve replacements (AVR) offer many potential haemodynamic advantages over their stented counterparts. By allowing a larger-sized valve to be implanted in a given annulus and preserving both the distensibility of the annulus and the geometry of the sinotubular junction, lower pressure gradients and higher effective orifice areas are seen on echo-doppler [1] . Unlike stented prostheses, exercise-induced gradient increases are not seen [2] . Nevertheless, opinions are divided as to the degree of clinical benefit, with some suggesting that these advantages do not necessarily translate into secondary gains of longevity, left ventricular (LV) mass regression and survival advantage unless left ventricular function is significantly impaired [3] .
Haemodynamic gains must be balanced, however, against disadvantages that include technical difficulty, a learning curve and a longer ischaemic time. There is a general acceptance that stentless valve implantation poses a greater technical challenge to the surgeon, although in selected centres that maintain a high-volume practice, this difference can be diminished to insignificant levels [4] .
The limited pool of homografts was supplemented from 1991 onwards by the introduction of stentless xenograft alternatives such as the Toronto Stentless Porcine Valve (TSPV), later the Toronto Root (St. Jude Medical Inc., St. Paul, MN, USA), and the composite Cryolife O'Brien (Cryolife International, Atlanta, GA, USA), although all are now discontinued. The Freestyle Aortic Root Bioprosthesis (Medtronic Inc., Minneapolis, MN, USA) was introduced in 1994 and its long-term follow-up data confirm its status as an excellent alternative to the homograft [5] .
To date however, stentless valves, including the Ross pulmonary autograft procedure with its unparalleled long-term outcomes [6] , represent but a small minority of aortic valve substitutes, limited to relatively few surgeons working in selected centres.
Failure of stentless valves
Modes of stentless valve failure can be divided into three categories as defined by the American Association for Thoracic Surgery, Society of Thoracic Surgeons and the European Association for Cardiothoracic Surgery [7] . Structural valve degeneration (SVD) encompasses regurgitation and/or stenosis caused by intrinsic valve changes including wear, calcification and leaflet tear (but not infection or thrombosis). Non-structural dysfunction is defined as causes that are extrinsic to the valve. Those most relevant to stentless valves include technical errors or dilatation of the valve annulus or sinotubular junction. Operated valve endocarditis represents a third category, with revision surgery associated with higher operative risk and poorer long-term outcome [8] .
Sadowski et al. [9] reviewed the outcomes of 655 aortic homografts over a 23-year period and found that aortic regurgitation (AR) was the predominant pathology at redo in 63% and aortic stenosis (AS) in 17%. O'Brien et al. [10] found that the recipient age affected the rates of structural valve degeneration, with patients of 20 years of age and under experiencing inferior durability. In a randomized trial of homograft vs Freestyle root replacement, homografts had higher calcium scores on electron beam computed tomography (CT) studies, with rapid calcification seen between 6 months and 3 years after surgery [11] . Correspondingly, Freestyle valves, with a shorter follow-up available appear to offer excellent long-term durability, with lower rates of reintervention at 8 years [5] .
Borger et al. [12] reported on 57 patients reoperated for TSPV or Freestyle valve failure. Structural valve degeneration was the aetiology of valve failure in 84% (with a further 12% having acute endocarditis) and aortic regurgitation the predominant valvular pathology. The comparative long-term durability of TSPVs has been found to be suboptimal, with cusp tears being the leading cause of valve failure [13] and evidence of focal calcification of the basal and commissural regions of the cusps [14] . Explanted Freestyle valves have shown evidence of cusp tears, T-cell driven inflammatory reaction, aortic media damage and root dilatation [15] .
Reintervention for stentless valve failure
In addition to the technical difficulty of implantation, reintervention is also widely regarded as a greater surgical challenge, although we previously found that reoperation for failure of a previous homograft carried no increased risk over other valve substitutes [16] . This is surprising, given the extensive calcification that befalls these prostheses [17] as illustrated in Fig. 1 . Rather, operative risk for redo AVR was affected by age >65 years, renal dysfunction, unstable preoperative status, New York Heart Association (NYHA) class III/IV dyspnoea, urgent or emergent operation, arrhythmia, chronic obstructive pulmonary disease (COPD), cardiogenic shock, impaired LV function or concomitant valvular procedure.
Historically, valve failure following stentless aortic valve replacement necessitated open revision surgery, typically with replacement of the entire aortic root. An alternative is 'valve in a valve' implantation [17] , whereby a stented valve is placed within the debrided stentless original. Little is known, however, about the comparative operative risk and medium to long-term outcomes of these two techniques. We have long considered that the valve-in-valve technique represents a more conservative, quicker surgical strategy, particularly in the high-risk scenario, but hypothesized that this would be weighed against a potential risk of paravalvular leak, patient prosthesis mismatch and an associated need for reintervention. In our practice, the decision to proceed with one or other method is invariably made intraoperatively, weighing up these perceived pros and cons while also considering factors such as tissue quality, calcification, annulus size and patient preference. The rapid rise of transcatheter aortic valve implantation (TAVI) now affords a third strategy, appearing to be well suited both physiologically and morphologically and with the potential to revolutionize the treatment of this condition [18, 19] . Approaching what may represent a new era, it seems highly pertinent to review the results of conventional open revision surgery in a centre with a longstanding interest in stentless aortic valve replacement.
PATIENTS AND METHODS
This retrospective study was conducted under the rules of, and with the approval of, the Royal Brompton and Harefield Clinical Governance Committee.
Patients
The operative records of the senior surgeon ( J.P.) were reviewed to identify the patients who had undergone redo surgery for failing stentless aortic valves over a 10-year period from January 2000 to March 2010. Where patients were reoperated during this period, the earlier procedure was used as the reference.
Patients were divided into either Group A, where a stented valve was implanted within the debrided stentless valve ('valve-in-valve') or Group B, where the stentless valve was completely excised and aortic root replacement performed ('redo root').
One hundred and twenty procedures were identified. Of these, four were reinterventions and six had clinical and macroscopic evidence of active endocarditis and were thus excluded.
Patient medical records, laboratory results and database returns to the Society of Cardiothoracic Surgeons of Great Britain and Ireland were reviewed and data collected regarding previous surgery, patient comorbidities, preoperative status, risk stratification (logistic EuroSCORE), postoperative course and complications. Follow-up status at early (<2 months), mid (12 months) and last review was gleaned from outpatient clinic records. Where patients had not been seen within 12 months, telephone consultation was performed to determine survival, symptomatic status and reintervention rate.
Echocardiography data within four time periods: preoperative, early (<2 months), mid (12 months) and last review were re-reviewed by a single reviewer (I.R.), to assess left ventricular outflow tract (LVOT) and aortic valve (AoV) haemodynamics, aortic regurgitation grade, left ventricular, septal and posterior wall dimensions and left ventricular ejection fraction (LVEF).
Of the 110 eligible cases identified, 65 were in Group A and 45 in Group B. Average age at surgery in Group A was 61.5 ± 14.2 years and 61.9 ± 12.1 years in Group B. About 75% of patients in Group A were male and 82% of Group B. The relative cases operated by year are demonstrated in Fig. 2 . It can be seen that a proportionally greater number of redo root cases were performed at the start of the decade and more valve-in-valve cases later in the decade, suggesting the existence of a long learning curve. Coronary angiography was performed in >95% of the patients.
Operative technique
In all cases, surgery was performed via redo median sternotomy. 
Statistical analysis
Statistical analysis was performed using Graphpad Prism 5 software (Graphpad, San Diego, CA, USA). Categorical variables were analysed with Fisher's exact test. Continuous variables are expressed as mean ± standard deviation and Mann-Whitney tests were used with 95% confidence intervals employed. In all cases, a value of P < 0.05 was considered as significant.
RESULTS
Patient comorbidities, preoperative status and risk stratification
Preoperative status and comorbidities of the two groups are outlined in Table 1 . Patients in Group A had a significantly higher body mass index (BMI) (P = 0.04) and were more likely to be classified as 'overweight' (P = 0.024). However, the prevalence of other cardiovascular risk factors, concurrent ischaemic heart disease, renal disease and respiratory disease were similar. Patients in Group B were significantly more likely to have suffered from neurological conditions such as cerebrovascular accident (CVA). Hereditary aortopathies such as Marfan syndrome (MFS) were uncommon. Patients in Group B were more likely to have undergone previous isolated aortic valve and/or root replacement (91 vs 74%, P = 0.0273), and the majority of prior aortic valve substitutes were homograft root replacements, subcoronary homografts and TSPVs. Group B included 2 patients who had undergone prior Ross pulmonary autograft procedures.
Preoperative NYHA symptomatic status was comparable between the two groups. Average LVEF was 57 ± 15% in Group A vs 58 ± 9% in Group B non significant (ns). About 80% of patients in Group A had predominantly aortic regurgitation vs 89% of patients in Group B, with the vast majority of patients suffering from moderate or severe aortic regurgitation. No significant differences in other echocardiography parameters were seen.
The mean logistic EuroSCORE for Group A was 14.8 ± 11.8 vs 12.0 ± 9.3 for Group B (ns).
Surgical procedures
Comparative procedural data are shown in Table 2 . While the majority of patients underwent second-or third-time procedures, it is notable that more than 10% of cases in both groups were fourth-or fifth-time sternotomies. Only one serious adverse event occurred during re-sternotomy, with accidental aortic injury necessitating unplanned replacement of the ascending aorta. The average interval from previous surgery was 10.9 ± 4.5 years (1.9-24.6 years) for Group A and 11.6 ± 5.9 years (0.2-29.0 years) for Group B (ns). Structural valve degeneration was the cause of valve failure in 99% of the patients in Group A vs 80% in Group B (P = 0.0029).
Of the valve-in-valve procedures, more than two-thirds of patients received a biological valve, predominantly Mosaic or Mosaic Ultra prostheses. Isolated aortic valve procedures were performed alone in 68 vs 64% (ns). Concomitant coronary artery bypass grafting (CABG) was performed in 6% of cases in Group A as opposed to 13% in Group B, although 2 of the cases in the latter represented salvage manoeuvres for ventricular dysfunction upon wean from CPB.
Review of the valve models implanted revealed that the majority of stented valves were of sizes 23 or 25 mm. Whilst acknowledging the pitfalls of comparing valve models on a size-for-size basis [20] , this represented a reduction in valve size of 0.8 mm ± 2.6 mm compared with the previous procedure, whereas redo root procedures resulted in the use of a valve substitute of, on average, 0.9 mm ± 2.9 mm larger than the original (P = 0.0194).
There was a highly significant difference in operative duration between the two groups in favour of the more conservative valve-in-valve strategy. For isolated aortic valve procedures, CPB durations were reduced by almost half, averaging 120 ± 20 min in Group A vs 217 ± 66 min in Group B (P < 0.0001) and ischaemic times of 77 ± 13 min vs 146 ± 26 min (P < 0.0001).
Postoperative complications, length of stay and 30-day outcome
Relative complications, length of critical care and inpatient stay and 30-day survival are described in Table 3 . The scale of surgery and impact of longer bypass times are perhaps reflected in the fact that Group B suffered almost twice the number of total complications than Group A: most notably the requirement for new permanent pacing systems (PPM) in 10 vs 29% (P = 0.023) and pleural effusions necessitating drainage in 8 vs 24% (P = 0.034). More neurological complications were seen after redo root procedures: 3 vs 13% (ns). Consequently, mean ventilation duration 1.7 ± 2.4 vs 4.4 ± 8.8 days, critical care stay 5.5 ± 8.8 vs 7.4 ± 10.5 days and postoperative length of stay 12.6 ± 10.7 vs 14.3 ± 12.3 days, were greater in Group B although the differences did not reach statistical significance.
In Group A, there were no intraoperative deaths and two deaths within 30 days, as opposed to three intraoperative deaths in the redo root group and a further two deaths within 30 days, equating to 30 day survival rates of 97 vs 89% (P = 0.12).
Follow-up status, echocardiography data and reinterventions
Follow-up status at early (<2 months), mid (1 year) and last clinical review are listed in Table 4 . Records of outpatient clinic reviews within 2 months of surgery were available for 87% of surviving patients in Group A and 90% of survivors in Group B. There was no difference in symptomatic status, with >80% of patients classified as NYHA I. At 1 year (range 8-16 months), records were found for 74 and 67% of surviving patients in the two groups, and again there was no significant difference between the two, with 75 and 81% classified as NYHA I and 20% of patients in both groups describing NYHA II class shortness of breath. Status at last review were collated for the two groups, with Group A averaging 
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3.7 ± 2.4 years vs 5.4 ± 3.0 years for Group B (P = 0.0046). The majority of patients remained free of shortness of breath (NYHA I, 76 vs 64%), and although more patients in Group B reported NYHA class II (19 vs 28%) or NYHA class III symptoms (6 vs 8%) the differences were not significant. Comparative echocardiography data for the two groups at the same time-points are presented in Table 5 . No differences in left ventricular outflow tract (LVOT) haemodynamics between the two groups were seen in any of the three follow-up periods. In contrast, differences in echo-doppler measurements of transvalvular haemodynamics between the two groups were highly significant, with valve-in-valve cases exhibiting gradients that were typically three times greater than redo root cases, but mean gradients averaging less than the 25-mmHg American Heart Association (AHA) threshold for categorization of mild aortic stenosis. Diminution of left ventricular end diastolic dimension (LVIDd) was seen in both groups: −0.9 ± 1.2 cm in Group A at 1 year vs −1.1 ± 0.8 cm in Group B (ns) and left ventricular ejection fractions were also comparable. Excluding the three patients who required reintervention for further structural valve degeneration and aortic regurgitation (listed below), no patients in either group have, to date, exhibited moderate or severe regurgitation. Only one valve-in-valve patient had a measurable paraprosthetic leak.
Survival and aortic valve reintervention
Including telephone consultations for patients not reviewed in the outpatients' clinic within the preceding 12 months, survival in Group A at 5.1 ± 2.7 years was 83 vs 76% at 7.3 ± 2.9 years for Group B. Aortic valve reinterventions are listed in Table 6 . At 5.1 ± 2.7 years, two valve-in-valve patients had required aortic valve reoperation. Of these, one patient required root replacement because of prosthetic valve endocarditis and the other received a second valve-in-valve because of structural valve degeneration of the previous Mosaic valve-in-valve prosthesis at 9.6 years. Of the three reinterventions for failure of redo roots, two patients suffered complications of previous endocarditis and the third was structural valve degeneration of a homograft root at 5.8 years. All three patients underwent a valve-in-valve procedure with a successful outcome.
DISCUSSION
Comparative outcomes
This retrospective review of a single surgeon's experience of redo surgery for failing, predominantly regurgitant, stentless aortic valves over a 10-year period, represents one of the largest follow-up studies in this area. Homografts (either root replacements or in a subcoronary configuration) represented approximately two-thirds of the failing valves encountered, having been implanted in large numbers within this centre and its partner hospital for >30 years by surgical pioneers in the field. TSPV xenografts comprise a further 21-31% of the group. The leading cause of valve failure was structural valve degeneration, and, unlike other studies in this area, active endocarditis cases were excluded. Patients underwent either redo freestanding aortic root replacement with reimplantation of the coronary arteries or simple debridement of the degenerative valve and implantation of a stented valve within the stentless valve, or 'valve-in-valve'.
In this study, 59% of patients underwent a valve-in-valve procedure. Similarly, Nowicki et al. [8] reported on 130 homograft reoperations, although only first-time reoperations were included. Repair of the homograft was performed in 5%, valve-in-valve in 62% and redo root replacement in 33%. Although the primary operator in the current study ( J.P.) had performed valve-in-valve procedures for >20 years, it is notable that the proportion of valve-in-valve procedures increased with time, with 46% of patients from 2000 to 2005 undergoing valve-in-valve replacement compared with 71% from 2006 to 2010, suggesting the presence of a long learning curve for this procedure. In four redo root patients, attempts had been made to perform valve-in-valve implantation, but had been prevented by inadequate annulus size in two cases and excessive calcification and inadequate tissue quality in the other two. No attempts were made to perform aortic root augmentation in this series. Some modes of stentless valve failure appear to render the remaining root and annulus structure more amenable to valve-in-valve implantation. Patients in the valve-in-valve group were more likely to have isolated cusp tears whereas redo root cases had either cusp tears or leaflet perforation as the leading modes of regurgitation.
Valve-in-valve implantation, with avoidance of dissection of a typically heavily diseased aortic root and reimplantation of the coronary arteries, was confirmed as the more conservative surgical strategy as evidenced by the absence of operative deaths, significantly shorter operative durations and reduced postoperative complications.
The 3-fold higher requirement for early postoperative permanent pacing systems in the redo root group is striking (29 vs 10%), not least because 12 vs 3% already had pacemakers at the time of surgery. Furthermore, a further 25% of those without devices went on to require one by late follow-up.
The 30-day operative mortality rates of 3% for valve-in-valve implantation and 11% after redo root replacement compare favourably with other reported series of stentless AVR reintervention. Byrne et al. [21] reported an operative mortality rate of 11% among 18 reoperations after homograft or Ross pulmonary autograft replacement, in which 78% received a stented valve in valve replacement. In Borger's review of reoperations for failing TSPVs and Freestyle valves, despite specifically attempting to preserve the pre-existing root wall, redo root replacement was necessary in 63% of patients with an overall operative mortality of 11% and 5-year survival of 79% [12] . Sadowski et al. [9] reported a series of 139 reoperations amongst 655 homografts implanted over a 23-year period, with valve-in-valve replacement achieved in 91% of cases, giving an impressively low combined 30-day mortality of only 3%. None of these studies looked specifically at the comparative clinical outcomes of the two techniques.
Valve-in-valve implantation resulted in an average valve diameter reduction of almost 1 mm, and although this is less than might reasonably be expected, comparison of valve models on a purely millimetre size-for-size basis appears to be of limited value [20] . To avoid this problem, Nowicki et al. [8] referenced the valve internal orifice diameter to patient size and reported that size discrepancies were greatest when a xenograft was implanted in a retained homograft root replacement, leading them to stress the importance of the completeness of debridement of annular scar tissue in achieving the maximum size of valve implant.
In this study, the resultant echo-doppler data demonstrating a 2-to 3-fold higher transvalvular gradient after valve-in-valve implantation are entirely in keeping with what would be expected based on the wider body of stented vs stentless valve haemodynamic data in the literature. What is more surprising, however, is the near absence of paravalvular leak and a comparable diminution of left ventricular dimensions seen in the two groups. Assessments of comparative left ventricular mass regression indices would have been desirable, but they were too infrequently measured for it to be achieved.
A comparison of the resultant symptomatic status at early (2 month) and mid (1 year) time points revealed no significant difference between the groups, with more than three quarters of patients reporting no limitations to their activities. Redo root patients had a significantly longer follow-up duration of 5.4 years ± 3.0 years vs 3.7 ± 2.4 years (P = 0.0062) in light of the changing proportion of operations performed with time, and were found to have inferior symptomatic status. A functional assessment such as the 6-minute walk test would be a valuable tool in assessing the outcomes of the two groups, but was not achievable for a variety of reasons, not least the advanced age and geographical spread of the subjects.
All cause mortality at 5.1 ± 2.7 years for valve-in-valve cases was 18 vs 24% at 7.3 ± 3.0 years for redo root cases. Among the two reinterventions at 5.1 ± 2.7 years in Group A and three reinterventions at 7.3 ± 3.0 years for Group B, clinical indications were either further structural valve degeneration or endocarditis. Non-structural degeneration was not seen.
CONCLUSIONS
In conclusion, for stentless aortic valve failure, in the absence of active endocarditis, valve-in-valve implantation represents a valid alternative to replacement of the entire aortic root, and one which can be performed with low operative risk, even after multiple previous sternotomies. Satisfactory access to, and debridement of, the aortic annulus in a typically heavily calcified aortic root are, of course, paramount. Only in a small minority of cases was valve-in-valve implantation precluded by inadequate annular dimensions or unworkable tissue quality. Although transvalvular gradients were significantly higher in the valve-in-valve group, the anticipated complications of paravalvular leak, inferior symptomatic status from patient prosthesis mismatch and reintervention were not seen at medium to longterm follow-up.
APPENDIX. CONFERENCE DISCUSSION
Dr K. François (Gent, Belgium): This presentation concerns a technically challenging group of patients undergoing reoperative surgery after previous stentless aortic valve replacement. By excluding endocarditis from your analysis and focusing solely on valve regeneration, the conclusions become, I think, more valid. However, both patient groups are probably not completely comparable, with, on the one hand, the incompetent stentless valve with a cusp tear and relatively little calcification, and, on the other hand, the heavily calcified homograft, as you have shown nicely on the first picture, where the severe wall destruction doesn't allow anything other than a complete root replacement.
I have three questions for you, which I will bring up one by one. How would you explain the higher mortality in the root replacement group given that the longer bypass and cross-clamp times don't seem to be reflected in a higher incidence of renal failure, respiratory complications or revisions?
Dr Finch: I should have stressed that I have excluded the intraoperative deaths. In the root replacement group there were five deaths, of which three were intraoperative, and most of these are, of course, ventricular dysfunction after an extremely lengthy bypass time. So therefore the complications as presented are perhaps skewed in that respect.
Dr François: Given the relatively short follow-up time of the valve-in-valve group, and the significantly higher peak and mean gradients in a relatively young patient group (you had a mean age of 61), do you feel confident about the long-term durability of this solution?
Dr Finch: I think so; I don't have any evidence to the contrary at the current time. Certainly perhaps some of our findings are a little bit surprising, but some of these patients have more than three years' follow-up, and we are not encountering any of them at all, with the exception of the one paravalvular leak in a patient with significant haemolysis who may become the fourth reintervention in the valve-in-valve group. We have no reason to suspect other deleterious outcomes.
Dr François: And in view of your results, do you continue to offer an aortic homograft to young adults or would you like to go for other solutions like aortic valve repair or a Ross, or maybe a simple bioprosthetic valve instead?
Dr Finch: I think patient choice is of paramount importance. Yes, we would consider offering all these options as somewhat of a transition at the moment and we will see what the trends are over the next few years. But I have no reason to discontinue offering these options. We are using a lot of Freestyle roots, as I am sure many do. Perhaps there has been a general switch, or perhaps there is a slight predominance now in our unit of Freestyle roots versus homografts in many instances, but by no means a large predominance.
Dr M. Jasinski (Katowice, Poland): You have raised an important issue, especially coming from a centre of excellence in terms of bioprosthetic stentless implantation and implementation of this method, considering both homografts and xenografts. However, the question which is pretty important for me is what were the criteria in choosing one of those treatments, whether it was a redo root, the whole root replacement, or valvein-valve? And the second question is, is there a kind of selection in this analysis? In other words, were all patients submitted to redo with a failing stentless valve or were there any patients who were not included in the study?
Dr Finch: Again, the pretty obvious answer is, patient preference is paramount here. You give them the choice: 'we can offer you perhaps both treatments and do you have a particular wish to have one if it is anatomically feasible'.
As regards selection, no, I don't think there is a particular tendency towards offering one versus the other, if there has not been a preference expressed. We are often surprised by just how calcified a valve can be, and yet with appropriate and aggressive (I do stress "aggressive") debridement, both strategies become possible. I wish to allay any misconception that excessive calcification necessarily precludes the valve-in-valve treatment; it does not with the required degree of debridement.
Dr Jasinski: To end my discussion, I would like to suggest a probable solution of the problem, which would, on the one hand, deal with the problem of postoperative gradients and patient-prosthesis mismatch, and the feasibility of a valve-in-valve procedure: TAVI as an option for a failing stentless valve is one which should be considered, especially because there is a considerable and increasing experience with this sort of procedure being performed in different centres.
Dr Finch: Our units are certainly now offering both treatments. But I do stress that, of course, for eight of the 10 years of this study, TAVI was clearly not an option available to us.
Dr T. Folliguet (Paris, France): What is your philosophy now in Brompton concerning homografts? What is the typical patient in whom you would use a homograft now in 2011?
Dr Finch: If one excludes the congenital and the Ross procedures from this, I think then one is probably left with the unequivocal indication of endocarditis above all else.
Dr Folliguet: Primary endocarditis or redo endocarditis? Dr Finch: I think both. It is probably the only indication that, up to me, is the most clear-cut from what I have seen at the practice at the end of it. I would defer this to Professor Pepper if he feels strongly either way.
Dr Folliguet: In France we don't have access to as many homografts as you probably have in London, so we reserve the homograft for failed or redo endocarditis, two or three times. So this is why. And we also found that it was very difficult to reoperate on failed homografts because of the calcification. What do you think, Dr Pepper? Dr J. Pepper (London, UK): It really has not been a problem for endocarditis, whether it is native or prosthetic valve endocarditis. So our situation is very similar to yours. We are privileged to have a very good homograft department, which not only provides valves for the UK but also exports. But with the decline in the number of transplantations, the number of homografts is much less than it used to be.
